Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.

COPD - 1 Aug 2013

Ma Shuren, Lin Yong Y, He Jiangtao, Rouhani Farshid N, Brantly Mark, Turino Gerard M

Abstract excerpt

BACKGROUND: Intravenous alpha-1 antitrypsin protein (AAT) augmentation is a prescribed therapy for severe, genetically determined, alpha-1 antitrypsin deficiency (AATD), a genetic basis for pulmonary emphysema. AAT, a predominant systemic inhibitor of neutrophil elastase thus far has not been shown to decrease elastin degradation in a significant number of patients on this therapy. The objective of this study was...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha 1-Antitrypsin
Share to alpha 1-Antitrypsin Deficiency

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers

Share to Bronchoalveolar Lavage Fluid

Share to Elastin

Share to Homozygote

Share to Leukocyte Elastase

Share to Trypsin Inhibitors

Source

Identifiers

PMID: 23560990
DOI: 10.3109/15412555.2013.771163

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation.PMID 23560990Read ↗

Alpha-1 Antitrypsin Augmentation TherapySemantic proximity Read ↗

Therapeutic Benefits of Recombinant Alpha1-Antitrypsin IgG1 Fc-Fusion Protein in Experimental EmphysemaSemantic proximity Read ↗

α1 Antitrypsin deficiency: current best practice in testing and augmentation therapy.Semantic proximity Read ↗

Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.Semantic proximity Read ↗

Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.Semantic proximity Read ↗

Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank.Semantic proximity Read ↗

Emerging drugs for alpha-1-antitrypsin deficiency.Semantic proximity Read ↗

A review of alpha-1 antitrypsin deficiency.Semantic proximity Read ↗

Augmentation Therapy for Severe Alpha-1 Antitrypsin Deficiency Improves Survival and Is Decoupled from Spirometric Decline-A Multinational Registry Analysis.Semantic proximity Read ↗

Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data.Semantic proximity Read ↗

The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.Semantic proximity Read ↗

Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.